Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-0169 in Relapsed or Refractory Multiple Myeloma
NCT04017130Phase 1Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT-0169 in multiple myeloma (MM), sponsored by Molecular Templates, Inc. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose up to 12 months, Treatment-emergent Adverse Events up to 12 months and 5 more. Started Feb 2020; status: terminated.
02
Drugs
MT-0169
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04017130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017130.